Tezepelumab Significantly Benefits Severe Asthma Regardless of Patient Sex
An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.